Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
RAPT Therapeutics Inc
RAPTCurrent price
0.88 USD
+0.0042 USD (+0.48%)
Last closed
0.87 USD
Company
www.rapt.com
ISIN
US75382E1091
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
115 426 920 USD
Yield for 12 month
-88.85 %
1Y
3Y
5Y
10Y
15Y
RAPT
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. Address: 561 Eccles Avenue, South San Francisco, CA, United States, 94080
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
5.00 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
–
Last Year
-3 551 000 USD
Current Quarter
–
Last Quarter
–
Key Figures RAPT
1 year
3 years
5 years
10 years
EBITDA
-134 898 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-41.13 %
PEG Ratio
–
Return On Equity TTM
-77.09 %
Wall Street Target Price
5.00 USD
Revenue TTM
–
Book Value
1.44 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-100.00 %
Dividend Yield
–
Gross Profit TTM
1 527 000 USD
Earnings per share
-3.19 USD
Diluted Eps TTM
-3.19 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics RAPT
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History RAPT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio TTM
–
Last Split Date
–
Stock Valuation RAPT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
677.37
Price Sales TTM
411.22
Enterprise Value EBITDA
-10.73
Price Book MRQ
0.61
Financials RAPT
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators RAPT
For 52 weeks
0.75 USD
8.58 USD
50 Day MA
1.11 USD
Shares Short Prior Month
2 672 136
200 Day MA
1.69 USD
Short Ratio
5.49
Shares Short
4 936 472
Short Percent
4.01 %
BeatStart